Obalon Therapeutics (Obalon Therapeutics) Cash And Cash Equivalents : $8.97 Mil (As of Mar. 2021)

View and export this data going back to 2016. Start your Free Trial

What is Obalon Therapeutics Cash And Cash Equivalents?

Obalon Therapeutics's quarterly cash and cash equivalents declined from Sep. 2020 ($5.51 Mil) to Dec. 2020 ($3.91 Mil) but then increased from Dec. 2020 ($3.91 Mil) to Mar. 2021 ($8.97 Mil).

Obalon Therapeutics's annual cash and cash equivalents declined from Dec. 2018 ($21.19 Mil) to Dec. 2019 ($14.06 Mil) and declined from Dec. 2019 ($14.06 Mil) to Dec. 2020 ($3.91 Mil).

Obalon Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for Obalon Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Obalon Therapeutics Cash And Cash Equivalents Chart

Obalon Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Cash And Cash Equivalents

Get a 7-Day Free Trial

72.98

21.11

21.19

14.06

3.91

Obalon Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Cash And Cash Equivalents	Get a 7-Day Free Trial															8.92	6.80	5.51	3.91	8.97

Obalon Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Obalon Therapeutics (NAS:OBLN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Obalon Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Obalon Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Obalon Therapeutics (Obalon Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Obalon Therapeutics Inc (NAS:OBLN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

5421 Avenida Encinas, Suite F, Carlsbad, CA, USA, 92008

Website

https://www.obalon.com

Obalon Therapeutics Inc is a medical device company that focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes Obalon Balloon System. Geographically, it derives all of its revenue from the United States.

Executives

Raymond V Dittamore	director	P O BOX 2050, GLENWOOD SPRINGS CO 81602
William J. Plovanic	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Sharon Stevenson	director	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ECINAS, SUITE F, CARLSBAD CA 92008
Douglas Fisher	director	587 PATROL RD, WOODSIDE CA 94062
Lesley H Howe	director
Kim P. Kamdar	director	C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Andrew P Rasdal	director, officer: President, CEO & Exec Chairman	C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Nooshin Hussainy	officer: Chief Financial Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Mark Brister	officer: Chief Technology Officer	C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Robert J Macdonald	officer: Chief Retail Officer	C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Amy Vandenberg	officer: Chief Clinical & Reg Officer	C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Nicole Vitullo	10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Arnold L Oronsky	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Gilbert H Kliman	10 percent owner	C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022